Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Genome editing of human embryos: to edit or not to edit, that is the question
Srinivasan Chandrasegaran, … , C. Korin Bullen, Dana Carroll
Srinivasan Chandrasegaran, … , C. Korin Bullen, Dana Carroll
Published August 28, 2017
Citation Information: J Clin Invest. 2017;127(10):3588-3590. https://doi.org/10.1172/JCI96962.
View: Text | PDF
Viewpoint

Genome editing of human embryos: to edit or not to edit, that is the question

  • Text
  • PDF
Abstract

Authors

Srinivasan Chandrasegaran, C. Korin Bullen, Dana Carroll

×

Figure 1

Genome editing of the MYBPC3ΔGAGT mutation by CRISPR-Cas9 and sgRNA injection into human embryos.

Options: View larger image (or click on image) Download as PowerPoint
Genome editing of the MYBPC3ΔGAGT mutation by CRISPR-Cas9 and sgRNA inje...
(A) (Top) Diagram of the WT and mutant (MUT) alleles and the sgRNA that specifically targets the mutant sequence. (Bottom) Possible genotypes from the editing of the paternal MYBPC3ΔGAGT mutant allele using CRISPR-Cas9 with and without ssODNs. (B) Blastomere genotype distribution in 4- to 8-cell embryos, arising after injection of CRISPR-Cas9 either into human S-phase zygotes or into M-phase MII oocytes. Because the sperm donor was heterozygous and the egg donors WT, about half the cells in control embryos were fully WT and half heterozygous. The paternal mutant allele is preferentially corrected using the homologous WT maternal chromosome in human embryos rather than the ssODNs provided by the investigator. Figure modified with permission from Nature (1). HDR, repaired allele resulting from homologous recombination that is indistinguishable from WT; NHEJ, insertions and deletions resulting from nonhomologous end joining; PAM, protospacer adjacent motif; sgRNA, single guide RNA.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts